Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H3 | Q13133 | 20/20 | 1.00 |
| ▸ | NR1H2 | P55055 | 19/20 | 1.00 |
| ▸ | RXRA | P19793 | 2/20 | 0.78 |
| ▸ | MEN1 | O00255 | 1/20 | 0.75 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.75 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.75 |
| ▸ | MAPT | P10636 | 1/20 | 0.75 |
| ▸ | VHL | P40337 | 1/20 | 0.75 |
| ▸ | RECQL | P46063 | 1/20 | 0.75 |
| ▸ | BLM | P54132 | 1/20 | 0.75 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3982005 | 0.99 | NR1H3 (0.98) | NR1H3NR1H2RXRAMEN1NR1I2 | |
| Hydrochloric Acid SCHEMBL5412814 | 0.92 | NR1H3 (0.86) | NR1H3NR1H2RXRAMEN1NR1I2 | |
| SCHEMBL4950865 | 0.90 | NR1H3 (0.82) | NR1H3NR1H2RXRAMEN1NR1I2 | |
| SCHEMBL3977525 | 0.90 | NR1H3 (0.81) | NR1H3NR1H2RXRAMEN1NR1I2 | |
| SCHEMBL13764649 | 0.90 | NR1H3 (0.81) | NR1H3NR1H2RXRAMEN1NR1I2 | |
| SCHEMBL13764648 | 0.90 | NR1H3 (0.81) | NR1H3NR1H2RXRAMEN1NR1I2 | |
| SCHEMBL3979043 | 0.90 | NR1H3 (0.81) | NR1H3NR1H2RXRAMEN1NR1I2 | |
| Hydrochloric Acid SCHEMBL3978393 | 0.89 | NR1H3 (0.80) | NR1H3NR1H2RXRAMEN1NR1I2 | |
| Hydrochloric Acid SCHEMBL3982885 | 0.89 | NR1H3 (0.80) | NR1H3NR1H2RXRAMEN1NR1I2 | |
| SCHEMBL4280646 | 0.88 | NR1H3 (0.79) | NR1H3NR1H2RXRAMEN1NR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060041164-A1 | Acid and ester compounds and methods of using the same | GLAXOSMITHKLINE LLC | 2006-02-23 | — | — | US | claimed |
| EP-1487776-A4 | ACID AND ESTER COMPOUNDS AND METHODS OF USING THE SAME | SMITHKLINE BEECHAM CORP (US) | 2005-05-25 | — | — | EP | claimed |
| EP-1487776-A1 | ACID AND ESTER COMPOUNDS AND METHODS OF USING THE SAME | SMITHKLINE BEECHAM CORPORATION (US) | 2004-12-22 | — | — | EP | claimed |
| WO-2003082802-A1 | ACID AND ESTER COMPOUNDS AND METHODS OF USING THE SAME | SMITHKLINE BEECHAM CORPORATION (US) | 2003-10-09 | — | — | WO | claimed |
| EP-3091970-B1 | LXR AGONISTS AND USES THEREOF | RGENIX INC (US) | 2020-10-28 | — | — | EP | disclosed |
| US-10669296-B2 | LXR agonists and uses thereof | RGENIX, INC. (US) | 2020-06-02 | — | — | US | disclosed |
| US-20170066791-A1 | LXR AGONISTS AND USES THEREOF | INSPIRNA, INC. | 2017-03-09 | — | — | US | disclosed |
| EP-3091970-A1 | LXR AGONISTS AND USES THEREOF | Rgenix, Inc. (US) | 2016-11-16 | — | — | EP | disclosed |
| WO-2015106164-A1 | LXR AGONISTS AND USES THEREOF | RGENIX, INC. (US) | 2015-07-16 | — | — | WO | disclosed |
| US-7560586-B2 | Acid and ester compounds and methods of using the same | SMITHKLINE BEECHAM CORPORATION (US) | 2009-07-14 | — | — | US | disclosed |
| US-7560586-B2 | Acid and ester compounds and methods of using the same | SMITHKLINE BEECHAM CORPORATION (US) | 2009-07-14 | — | — | US | disclosed |
| US-7560586-B2 | Acid and ester compounds and methods of using the same | SMITHKLINE BEECHAM CORPORATION (US) | 2009-07-14 | — | — | US | disclosed |
| US-20060041164-A1 | Acid and ester compounds and methods of using the same | GLAXOSMITHKLINE LLC | 2006-02-23 | — | — | US | disclosed |
| EP-1487776-A4 | ACID AND ESTER COMPOUNDS AND METHODS OF USING THE SAME | SMITHKLINE BEECHAM CORP (US) | 2005-05-25 | — | — | EP | disclosed |
| EP-1487776-A1 | ACID AND ESTER COMPOUNDS AND METHODS OF USING THE SAME | SMITHKLINE BEECHAM CORPORATION (US) | 2004-12-22 | — | — | EP | disclosed |
| WO-2003082802-A1 | ACID AND ESTER COMPOUNDS AND METHODS OF USING THE SAME | SMITHKLINE BEECHAM CORPORATION (US) | 2003-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10669296-B2 | LXR agonists and uses thereof | NR1H3, NR1H2, NR1H4 | NR1H3 1/4885NR1H2 2/4885RXRA 13/4885 |
| US-20170066791-A1 | LXR AGONISTS AND USES THEREOF | NR1H3, NR1H2, NR1H4 | NR1H3 1/4885NR1H2 2/4885RXRA 13/4885 |
| US-20060041164-A1 | Acid and ester compounds and methods of using the same | NR1H3, NR1H2, PPARA | NR1H3 1/4885NR1H2 2/4885RXRA 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.